Share
News

Michigan Hospital Tries To Treat Patients with Hydroxychloroquine; FDA Refuses To Allow It

Share

A month-old request from a Michigan hospital for emergency use authorization to treat COVID-19 patients with hydroxychloroquine has been denied by the U.S. Food and Drug Administration.

The Detroit-area Henry Ford Health System requested to use the anti-malaria drug on a group of patients “meeting very specific criteria” on July 6, MLive reported.

The FDA denied the hospital’s request this week, Dr. Adnan Munkarah, the system’s executive vice president and chief clinical officer, confirmed in a Thursday statement.

The denial of the emergency use authorization request will not impact the hospital’s “randomized, double-blind study of hydroxychloroquine as a preventative treatment,” MLive reported, citing a hospital spokesperson.

The use of hydroxychloroquine has been controversial for months.

Trending:
Watch: Actor Drops Devastating Truth Bomb on Alec Baldwin, Shows Why 'Rust' Gun Couldn't Have Fired Itself

A May 22 study posted in The Lancet used data from analytics company Surgisphere to conclude that coronavirus patients taking chloroquine or hydroxychloroquine were more likely to die in the hospital, Science reported.

Within days of the study’s publication, randomized trials of hydroxychloroquine came to a stop, including part of the World Health Organization’s trial of potential COVID-19 treatments. However, the data used in that study had been scrutinized and described as “flawed,” and it was ultimately retracted.

When President Donald Trump began taking hydroxychloroquine as a way to prevent him from contracting COVID-19, the mainstream media and Democrats mocked him for it.

Last month, Henry Ford Health System published an observational study in the International Journal of Infectious Diseases that found hydroxychloroquine helped patients survive COVID-19 while in the hospital.

Do you think COVID-19 patients who want to be treated with hydroxychloroquine should be allowed to take the drug?

Researchers studied a group of 2,541 hospitalized patients and found mortality rates were substantially reduced when patients were treated with hydroxychloroquine.

The study found that 13 percent of patients treated with just hydroxychloroquine died compared to 26.4 percent not treated with the drug.

“Overall crude mortality rates were 18.1 percent in the entire cohort, 13.5 percent in the hydroxychloroquine alone group, 20.1 percent among those receiving hydroxychloroquine + azithromycin, 22.4 percent among the azithromycin alone group, and 26.4 percent for neither drug,” the study’s report read.

Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, called the study “flawed” because it wasn’t a randomized, placebo-controlled trial, MLive reported.

“The Henry Ford Hospital study that was published was a non-controlled, retrospective cohort study that was confounded by a number of issues including the fact that many people who received hydroxychloroquine were also receiving corticosteroids, which we know from another study gives a clear benefit in reducing deaths with advanced disease,” he said.

Related:
Vax Mandates for Holiday Travelers? Psaki Makes Chilling Admission on Possible Domestic Travel Restrictions

Munkarah wrote in an Aug. 3 letter that the hospital will not make any comment about its study outside the medical community.

“Unfortunately, the political climate that has persisted has made any objective discussion about this drug impossible, and we are deeply saddened by this turn of events,” he wrote.

“Our goal as scientists has solely been to report validated findings and allow the science to speak for itself, regardless of political considerations.”

The hospital is still using remdesivir and convalescent plasma to treat its patients “where clinically indicated,” a spokesperson told MLive.

Truth and Accuracy

Submit a Correction →



We are committed to truth and accuracy in all of our journalism. Read our editorial standards.

Tags:
, , , , ,
Share
Erin Coates was an editor for The Western Journal for over two years before becoming a news writer. A University of Oregon graduate, Erin has conducted research in data journalism and contributed to various publications as a writer and editor.
Erin Coates was an editor for The Western Journal for over two years before becoming a news writer. She grew up in San Diego, California, proceeding to attend the University of Oregon and graduate with honors holding a degree in journalism. During her time in Oregon, Erin was an associate editor for Ethos Magazine and a freelance writer for Eugene Magazine. She has conducted research in data journalism, which has been published in the book “Data Journalism: Past, Present and Future.” Erin is an avid runner with a heart for encouraging young girls and has served as a coach for the organization Girls on the Run. As a writer and editor, Erin strives to promote social dialogue and tell the story of those around her.
Birthplace
Tucson, Arizona
Nationality
American
Honors/Awards
Graduated with Honors
Education
Bachelor of Arts in Journalism, University of Oregon
Books Written
Contributor for Data Journalism: Past, Present and Future
Location
Prescott, Arizona
Languages Spoken
English, French
Topics of Expertise
Politics, Health, Entertainment, Faith




Conversation

The Western Journal is pleased to bring back comments to our articles! Due to threatened de-monetization by Big Tech, we had temporarily removed comments, but we have now implemented a solution to bring back the conversation that Big Tech doesn't want you to have. If you have any problems using the new commenting platform, please contact customer support at commenting-help@insticator.com. Welcome back!